NHS Framework for the supply of Licensed Antiretroviral Therapy (ART) 1 Nov 2024
£626,522,476
value
GBP
28 Oct 2024
awarded
13
suppliers named
Who
| Buyer | NHS England — not a council we hold |
| Supplier | Abbvie Ltd |
| Supplier | Amarox Limited |
| Supplier | Dr.Reddy's Laboratories (UK) Limited |
| Supplier | Gilead Sciences Limited |
| Supplier | Janssen-Cilag Ltd |
| Supplier | Lupin Healthcare (UK) Limited |
| Supplier | Macleods Pharma UK Limited |
| Supplier | Mawdsley-Brooks & Co Ltd |
| Supplier | Merck Sharpe & Dohme (UK) Limited |
| Supplier | Milpharm Ltd/aurobinbdo Primary |
| Supplier | MSN Laboratories Europe Limited |
| Supplier | Mylan |
| Supplier | ViiV Healthcare UK Ltd |
What
Project title: NHS Framework for the supply of Licensed Antiretroviral Therapy (ART) for the treatment of HIV (Lot 1) & For the provision of a service to supply over labelled Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) Packs for the prevention of HIV (Lot 2) 1st November 2024 Offer reference number: CM/PHS/24/5709 Period of framework agreement: 1st November 2024 to 31st October 2026 with an option to extend (at the Authority's discretion) for a further period (or periods) up to a total of 24 months.
Dates and source
| Runs | 1 Nov 2024 to 31 Oct 2026 |
| OCID | ocds-b5fd17-7ebc8e72-38c5-4910-9915-28bc0d6ff58a |
| Notice | Read it on Contracts Finder |
Figures are as published An award value in OCDS may be a framework ceiling rather than a sum anyone expects to spend, so a large figure here is not evidence of a large purchase.